Patents by Inventor Cho-Lea Tso

Cho-Lea Tso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250
    Publication number: 20180371411
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Application
    Filed: June 27, 2018
    Publication date: December 27, 2018
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
    Patent number: 10035981
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250
    Publication number: 20160376556
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Application
    Filed: July 1, 2016
    Publication date: December 29, 2016
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
    Patent number: 9409965
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: August 9, 2016
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250
    Publication number: 20150010587
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Application
    Filed: May 2, 2014
    Publication date: January 8, 2015
    Applicant: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Kidney specific tumor vaccine directed against kidney tumor antigen G-250
    Patent number: 8741306
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: June 3, 2014
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250
    Publication number: 20100129313
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Application
    Filed: June 5, 2009
    Publication date: May 27, 2010
    Applicant: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
    Patent number: 7572891
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: August 11, 2009
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
    Publication number: 20020058041
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Application
    Filed: February 13, 2001
    Publication date: May 16, 2002
    Inventors: Arie Belldegrun, Cho-Lea Tso